Table 1.
Clinical features of patients included in the study.
| Patient ID | Age (Years) | Sex | TNM | Stage | Survival | KRAS G12V (Copies/mL) | Fractional Abundance (%) |
|---|---|---|---|---|---|---|---|
| 53 | 85 | M | T3N0M0 | IIa | 6 years | 7.50 | 62.79 |
| 113 | 80 | F | T1N0M0 | I | >2 years | 0.00 | 40.42 |
| 118 | 64 | M | T3N2M1 Liver | IV | >2 years | 25.00 | 6.16 |
| 130 | 49 | F | T3N1M1 Liver | IV | 8 months | 197.5 | 20.60 |
| 158 | 84 | M | T4N0M0 | IIb | 1 year | 11.25 | 34.87 |
| 220 | 69 | M | T4N2M1 Bone | IV | 2 months | 55.00 | 38.80 |
| 257 | 85 | M | T3N0MX | IIa | 8 days | 46.25 | 53.20 |
| 258 | 86 | M | T3N0MX | IIa | 20 days | 110.00 | 33.70 |
| 522 | 77 | M | T3N0M0 | IIa | 18 months | 13.75 | 23.76 |
| 532 | 60 | M | T4N1M2 Liver Lung | IV | 10 days | 2412.5 | 77.82 |
This cohort of KRAS G12V patients showed a markedly poor clinical outcome, high rate of post-operative complications, and short time of survival.